About
Coronis Neurosciences is a specialty pharmaceutical company focused on the development of therapies for neurocognitive and neurodegenerative disorders. Coronis owns a pipeline of several clinical- and preclinical-stage molecules and strives to build value through the clinical development of proprietary formulated drugs. The company's pipeline includes CP201, its leading drug, developed to treat ADNP syndrome. CP201 is a trans-nasally delivered peptide (NAP) developed for the treatment of ADNP syndrome in children. ADNP syndrome, an autism spectrum disorder, is a rare neurogenetic disease caused by de novo mutations in the ADNP gene. Coronis also develops CP101, a drug to treat cognitive impairment associated with schizophrenia (CIAS) using a proprietary new small peptide.